{"filings":[{"id":1000320,"accession_number":"0001193125-26-267563","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-06-11T20:15:15+00:00","items":["5.07"],"status":"ready","headline":"All four proposals approved at Cardiff Oncology 2026 annual meeting, including equity plan increase to 15.15M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; broker non-votes of ~22.3M shares for each.","Ratification of BDO USA as independent auditor for FY2026: 40.24M for, 1.07M against.","Amendment to 2021 Equity Incentive Plan increasing authorized shares to 15.15M approved: 10.74M for, 8.06M against.","Advisory say-on-pay vote on named executive officer compensation approved: 17.12M for, 1.77M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":816120,"accession_number":"0001193125-26-254658","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-06-03T12:30:20+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology furnishes investor presentation with Phase 2 CRDF-004 interim results","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers interim data from randomized Phase 2 CRDF-004 trial of onvansertib + SoC in first-line RAS-mutated mCRC.","Presentation also details registrational study plans for onvansertib in this indication.","No specific efficacy or safety endpoints were disclosed in the filing itself; details are in furnished Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748876,"accession_number":"0001193125-26-248711","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-05-29T21:11:12+00:00","items":["1.01"],"status":"ready","headline":"NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.","NMS claims Cardiff failed to correct inventorship to include Dr. Barbara Valsasina on two U.S. patents and failed to use commercially reasonable efforts for onvansertib.","Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and declaratory judgment that it did not breach the agreement.","Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.","Dispute centers on rights to onvansertib, a key pipeline asset; potential impact on development timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":528877,"accession_number":"0001193125-26-231040","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-05-19T21:01:02+00:00","items":["8.01"],"status":"ready","headline":"Cardiff Oncology sues Nerviano Medical Sciences over onvansertib license inventorship dispute","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit in SD California for injunctive relief and declaratory judgment it did not breach license agreement for onvansertib.","Dispute stems from NMS allegation that Cardiff failed to name an NMS employee as joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173.","Cardiff maintains no breach occurred; agreement does not require naming NMS employees on inventions made solely by Cardiff.","NMS sent written notice of alleged material breach on February 24, 2026, as previously disclosed.","Judicial intervention sought after prior discussions failed to resolve the disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442876,"accession_number":"0001213037-26-000013","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-05-14T20:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.","Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.","Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.","Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.","Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":41000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91737,"accession_number":"0001193125-26-149623","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.","Josh Muntner named CFO effective April 6, 2026; base salary $475K, 40% bonus; granted options to buy 486,650 shares at $1.58.","Ajay Aggarwal appointed COO effective April 27, 2026; base salary $490K, 40% bonus; expects 400,000 stock options.","Muntner has 25+ years biopharma finance experience, previously CFO at Imvax and Mesoblast, raised over $300M combined.","Dr. Aggarwal brings 15+ years pharma experience, most recently SVP Clinical Development at Aclaris Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91736,"accession_number":"0001193125-26-140152","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.","Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.","Levine's vested options exercisable for 12 months after separation date.","Erlander resigns from board of directors effective March 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102017,"accession_number":"0001193125-26-068668","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology furnishes Feb 2026 corporate presentation; no material news","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate slide presentation furnished as Exhibit 99.1 for investor meetings.","Presentation highlights onvansertib development pipeline and opportunity.","No financial results, guidance, or operational milestones disclosed.","Routine Regulation FD disclosure; no material changes to business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102016,"accession_number":"0001193125-26-067476","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Phase 2 mCRC data: ORR 72.2% vs 43.2% SoC, PFS HR 0.37; plans registrational program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.","Plans to advance 30 mg dose into registrational program; detailed data and FDA discussions expected H1 2026.","Cash $58.3M as of Dec 31, 2025; funds operations into Q1 2027. Total op ex $49.6M, slight increase from $49.3M in 2024.","Executive changes: Mani Mohindru appointed interim CEO; Brigitte Lindsay promoted to CAO; search for permanent CEO/CFO ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102015,"accession_number":"0001193125-26-024375","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.","Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).","Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.","Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.","Conference call today at 8:30 a.m. ET to discuss results and strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118359,"accession_number":"0001193125-25-269492","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.","Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.","Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.","Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.","Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":350000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134796,"accession_number":"0000950170-25-099631","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.","Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.","Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.","Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.","Company expects to provide update on first-line mCRC program by Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151713,"accession_number":"0001641172-25-016659","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardiff Oncology stockholders approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.","Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.","Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.","Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151712,"accession_number":"0000950170-25-087369","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.","Dr. Roger Sidhu appointed CMO; previously at Amgen, Treadwell Therapeutics, Roivant Sciences.","Sidhu receives $515K base salary, 45% target bonus, and option for 600K shares at $3.86 vesting over 4 years.","Company to report additional clinical data from Phase 2 CRDF-004 trial in RAS-mutated mCRC on July 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151711,"accession_number":"0000950170-25-066947","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology completes enrollment in Phase 2 onvansertib trial for RAS-mutated mCRC; Q1 cash $79.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Phase 2 CRDF-004 trial of onvansertib + SoC for first-line RAS-mutated mCRC across 41 U.S. sites.","Received second USPTO patent (No. 12,263,173) for onvansertib + bev in all bev-naïve mCRC patients, expiring no earlier than 2043.","Cash and investments $79.9M as of March 31, 2025; projected runway into Q1 2027.","Q1 2025 operating expenses $14.5M (up from $11.1M YoY); net cash used in ops $12.8M (up from $7.7M YoY).","Additional CRDF-004 clinical data expected in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":109000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170570,"accession_number":"0000950170-25-029065","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).","Raised $40M oversubscribed registered direct offering; cash runway extended into Q1 2027.","Full-year 2024 net cash used $37.7M; operating expenses $49.3M, up $3.4M YoY.","USPTO issued patent for onvansertib + bev in bev-naïve KRAS-mut mCRC, expiring no earlier than 2043.","Additional CRDF-004 clinical data expected in 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":683000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170569,"accession_number":"0000950170-25-002076","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cardiff Oncology amends and restates its bylaws effective January 3, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors approved Amended and Restated Bylaws on January 3, 2025.","The amended bylaws were filed as Exhibit 3.1 to the Form 8-K.","No change in fiscal year was reported in connection with the amendment.","The company is incorporated in Delaware and trades on Nasdaq under CRDF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187562,"accession_number":"0000950170-24-134970","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.","Net proceeds to fund onvansertib clinical costs for RAS-mutated metastatic colorectal cancer (mCRC).","New mutual fund and healthcare dedicated investors participated; existing investors also supported.","Expected close Dec 11, 2024; 90-day lock-up for directors and officers on share sales.","TD Cowen lead bookrunner; William Blair, H.C. Wainwright, Craig-Hallum also underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187561,"accession_number":"0000950170-24-134749","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).","Onvansertib well-tolerated; no major or unexpected toxicities at either dose.","Additional CRDF-004 clinical data expected in 1H 2025.","Conference call held Dec 10, 2024 at 8:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187560,"accession_number":"0000950170-24-123303","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.","Net cash used in operations: $10.5M in Q3 2024, up from $8.0M in Q3 2023.","Total operating expenses $12.8M for Q3 2024, an increase of $1.8M YoY.","Initial data readout from first-line RAS-mutated mCRC CRDF-004 trial expected by end of 2024.","Phase 2 trial in second-line KRAS-mutant mCRC published in Journal of Clinical Oncology; bev naïve patients had ORR 77% and mPFS 14.9 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":532000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204040,"accession_number":"0001628280-24-036122","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q2 cash $60.3M; CRDF-004 readout expected 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $60.3M as of June 30, 2024; runway to Q3 2025.","Net cash used in ops $9.2M in Q2 2024 vs $7.1M in Q2 2023.","Total operating expenses $12.7M for Q2 2024, up $0.4M YoY.","CRDF-004 trial for first-line RAS-mutated mCRC data readout expected in 2H 2024.","Preclinical data published on onvansertib + olaparib in olaparib-resistant ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":368000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220745,"accession_number":"0001628280-24-029108","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardiff Oncology shareholders approve increase in shares under 2021 equity plan to 8.15M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: For votes ranged 15.2M–15.5M; no director received >601K abstentions.","Ratification of BDO USA as auditor for FY2024 approved: 27.1M For, 0.26M Against, 0.33M Abstain.","Amendment to 2021 Equity Incentive Plan increasing authorized shares to 8,150,000 approved: 13.1M For, 2.4M Against, 0.35M Abstain.","Advisory vote on executive compensation passed: 13.3M For, 2.1M Against, 0.41M Abstain.","All proposals passed; broker non-votes noted for director election, equity plan, and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220744,"accession_number":"0001628280-24-026295","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology rescinds 1.7M options, regrants same subject to stockholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board rescinded 1,697,712 options granted on March 7, 2024 at $3.51/share.","Board regranted 1,697,712 options at same $3.51 strike, contingent on June 20, 2024 stockholder vote.","Stockholder approval required to increase shares available under 2021 Equity Incentive Plan.","Bylaw amended to align voting standards: plurality for directors, majority for other matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220743,"accession_number":"0001628280-24-020010","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.","Operating expenses $11.1M, down $1.0M YoY; net cash used in ops $7.7M.","ONSEMBLE trial: bev naïve patients on onvansertib+SoC had 50% ORR vs 0% for SoC alone.","Initial readout from first-line RAS-mutated mCRC Phase 2 CRDF-004 trial expected 2H 2024.","Preclinical AACR data showed onvansertib activity in RAS wild-type mCRC, SCLC, and ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220742,"accession_number":"0001628280-24-015247","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology AACR data: onvansertib shows 73% ORR in bev-naive RAS-mutated mCRC vs 19% in bev-exposed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).","Onvansertib inhibits hypoxia pathway via HIF1α regulation, reducing tumor vascularization; combo with bevacizumab enhances reduction.","In RAS WT mCRC PDX models, onvansertib as monotherapy induced stasis/regression in 70% (14/20) of models; combo with cetuximab in 90% (18/20).","In SCLC cisplatin-resistant PDX models, onvansertib + paclitaxel led to tumor regression lasting 2 months post-treatment.","CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC to randomize 90 patients to onvansertib 20mg or 30mg plus SoC vs SoC alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240360,"accession_number":"0001628280-24-007972","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.","ONSEMBLE: 50% ORR (2/4) in bev naïve patients on onvansertib+SoC vs 0% in control; no responses in bev exposed.","First patient dosed in Phase 2 first-line CRDF-004 trial for RAS-mutated mCRC; topline data expected mid-2024.","Pfizer Ignite handling clinical execution; FDA accepted ORR as endpoint for potential accelerated approval.","FY2023 operating expenses $45.9M, net cash used $30.9M; decrease from $33.8M in FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240359,"accession_number":"0001628280-24-000780","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology presents onvansertib data: 73% DCR in 2L KRAS-mut mCRC; FDA Type C meeting supports accelerated path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.","FDA Type C meeting (June 2023) agreed on mCRC development plan supporting potential accelerated approval.","Topline data from 1st-line RAS-mutated mCRC trial expected mid-2024.","Cash runway extends into 2025; collaboration with Pfizer under Pfizer Ignite program.","Preclinical data show onvansertib + bevacizumab reduces tumor size and vascularization in KRAS G12V model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257861,"accession_number":"0001628280-23-036386","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.","FDA agreed on ORR as interim endpoint for accelerated approval; Phase 3 registrational trial planned contingent on CRDF-004.","mPDAC CRDF-001: ORR 19% (4/21 evaluable) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo for SoC alone.","Phase 2 SCLC monotherapy cleared to continue enrollment after safety review of first six patients.","Cash, equivalents, and short-term investments $81.4M; net cash burn Q3 $8.0M; runway into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":332000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275209,"accession_number":"0001628280-23-033014","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.","Biomarker trial: single-agent onvansertib reduced Ki67 by 86% and CA19-9 by 28% in refractory mPDAC.","Plans first-line mPDAC investigator-initiated trial of onvansertib + Gemzar/Abraxane at OHSU.","SCLC Phase 2: preliminary single-agent activity; safety confirmed; trial continues enrolling.","Conference call scheduled for Sept 26, 2023 at 5pm ET to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275208,"accession_number":"0001628280-23-028563","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"Cardiff Oncology shifts lead program to first-line RAS-mutated mCRC; Q2 cash burn $7.1M, runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.","Cash $89.4M as of June 30, 2023; net cash used in operations $7.1M in Q2; runway into 2025.","Expanded Pfizer relationship: Pfizer Ignite to handle clinical execution of CRDF-004 Phase 2 trial.","Operating expenses $12.3M for Q2 2023, up from $10.5M in Q2 2022 due to higher headcount and stock-based compensation.","Upcoming milestones: mPDAC data Q3'23, SCLC data Q3'23, TNBC data Q4'23/Q1'24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":191000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275207,"accession_number":"0001104659-23-088391","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology to Advance Onvansertib to First-Line mCRC, Partners with Pfizer Ignite for New Trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.","Launches CRDF-004 Phase 2 trial with 90 patients; interim topline results expected mid-2024.","Pfizer Ignite will support clinical execution; expands relationship from Pfizer's 2021 equity investment.","Discontinues ONSEMBLE second-line trial to focus resources on first-line program.","Cash position of $89.4M as of June 30, 2023, sufficient to fund operations into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275206,"accession_number":"0001628280-23-025483","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardiff Oncology grants 50,016 stock options to new employee as inducement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Grant of non-qualified stock options for 50,016 shares at $1.49 per share.","Options vest over 4 years: 25% after 1 year, then monthly for 36 months.","Grant made as inducement material to new employee's hiring under Nasdaq Rule 5635(c)(4).","One new employee received the award on July 24, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292643,"accession_number":"0001628280-23-022757","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardiff Oncology grants 40,032 stock options to new employee as inducement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Non-qualified stock options to purchase 40,032 shares granted to one new employee on June 20, 2023.","Exercise price of $1.56 per share equals closing price on grant date.","Options vest over 4 years: 25% at 1-year anniversary, then monthly over remaining 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292642,"accession_number":"0001628280-23-022271","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardiff Oncology's 2023 annual meeting results: all director nominees elected, BDO ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected with votes ranging from 12.5M to 14.1M for; broker non-votes ~12.67M.","Ratification of BDO USA as auditor for FY2023 approved with 26.56M for, 0.56M against, 0.18M abstain.","Advisory vote on executive compensation frequency: 1-year option approved with 13.68M votes; board sets annual say-on-pay.","Advisory vote on named executive officer compensation approved: 11.92M for, 2.42M against, 0.29M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292641,"accession_number":"0001628280-23-015693","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.","First patient dosed in Phase 2 ONSEMBLE trial of onvansertib for KRAS/NRAS-mutated metastatic CRC.","Appointed Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer.","Operating expenses $12.1M in Q1 2023, up from $11.1M in Q1 2022.","Net cash used in operations $8.7M in Q1 2023, compared to $10.2M in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":83000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313292,"accession_number":"0001628280-23-007567","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cardiff Oncology confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company issued 8-K confirming it holds no cash deposits or securities at SVB.","Disclosure made on March 10, 2023 amid SVB collapse concerns.","No financial impact or loss from the bank failure.","Ticker CRDF traded on Nasdaq; no change to operations or cash position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313291,"accession_number":"0001628280-23-006049","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.","Total operating expenses $40.3M for FY2022, up $11.1M from FY2021; net cash used in operations $33.8M.","Phase 1b/2 mCRC trial: ORR 35% (n=48), median PFS 9.3 months; bevacizumab-naïve subgroup ORR 69%, mPFS 13.5 months.","Appointed Fairooz Kabbinavar as CMO, Tod Smeal as CSO, Charles Monahan as SVP Regulatory Affairs.","Upcoming data readouts: mPDAC and SCLC in Q2/Q3 2023; TNBC in Q4 2023/Q1 2024; ONSEMBLE mCRC randomized data in Q3/Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313290,"accession_number":"0001628280-23-002037","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Cardiff Oncology appoints Fairooz Kabbinavar as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary $480,000, target bonus 45% of base, plus option grant.","Granted non-qualified option for 425,000 shares at $1.75/share exercise price.","Options vest over 4 years: 25% after 12 months, then monthly over 36 months.","Dr. Kabbinavar has 30+ years experience; lead investigator for bevacizumab mCRC approval trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331820,"accession_number":"0001628280-22-028200","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q3 cash burn $7.5M; Phase 1b/2 mCRC data show 35% ORR; ONSEMBLE trial on track for Q4 activation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $114M as of Sep 30, 2022; projected runway into 2025.","Q3 2022 net cash used in operations $7.5M vs $5.5M in Q3 2021.","Phase 1b/2 mCRC trial: ORR 35% (n=48), mPFS 9.3 months, mDoR 11.7 months.","ONSEMBLE randomized Phase 2 trial in KRAS/NRAS-mutated mCRC activation expected Q4 2022.","Bevacizumab-naïve subgroup ORR 69% and mPFS 13.5 months vs historical ~25% and 6.9 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":258000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331819,"accession_number":"0001628280-22-025855","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology posts updated corporate presentation on onvansertib clinical pipeline","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers onvansertib as a PLK1 inhibitor with potential in KRAS-mutated cancers.","Highlights ongoing Phase 1b/2 trials in mCRC, mPDAC, TNBC, and SCLC with historical ORR benchmarks.","Includes strategic goals for 2022-2025: demonstration, confirmation, and positioning for registration.","No specific new clinical data or financial guidance announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349297,"accession_number":"0001628280-22-024744","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Cardiff Oncology plans randomized Phase 2 mCRC trial (ONSEMBLE) with topline data in 2H 2024; cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2 mCRC data show ORR 35%, mPFS 9.3 mo, median DoR 11.7 mo; historical controls ORR 5-13%, mPFS 4.5-5.7 mo.","ONSEMBLE trial to enroll ~150 patients randomized 1:1:1 to SoC ± 20/30 mg onvansertib; primary endpoint ORR.","Phase 2 PDAC trial: 1 PR, 3 SD in 5 evaluable patients; additional data expected Q2/Q3 2023.","Company stops independent funding of prostate cancer program; will focus on mCRC and PDAC.","Cash resources expected to fund operations into 2025; investigator-initiated trials in TNBC and SCLC ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349296,"accession_number":"0001628280-22-024362","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardiff Oncology announces ESMO 2022 posters showing onvansertib overcomes irinotecan resistance in RAS-mutated mCRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).","Abstract 397P: Early ≥90% decrease in KRAS MAF after one cycle predicts higher ORR and longer PFS in ongoing Phase 1b/2 trial.","Additional findings from EAP and trial data to be released during ESMO, subject to embargo policies.","Conference call and webcast on Sept 12, 2022 at 4:30 PM ET to discuss clinical and corporate update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349295,"accession_number":"0001628280-22-021064","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q2 2022: $122M cash; preclinical ovarian data shows onvansertib + olaparib survival benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.","R&D expenses rose to $7.45M from $4.12M YoY, driven by CMC and clinical pharmacology studies for onvansertib.","Preclinical ovarian cancer data at AACR: onvansertib + olaparib showed statistically significant survival benefit vs either agent alone in three PDX models.","Phase 2 mCRPC trial: 75% (15/20) of most dose-dense arm achieved stable disease or partial response at 12 weeks; response correlated with PTEN/MTOR mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":165000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366194,"accession_number":"0001628280-22-017114","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K/A","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cardiff Oncology shareholders reject advisory vote on executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected voting results show say-on-pay failed: 7.93M For, 7.36M Against, 2.02M Abstain, 12.06M broker non-vote.","All seven director nominees elected; BDO USA ratified as auditor; amendment to 2021 Omnibus Equity Plan approved.","Amendment filed to correct original 8-K error in Proposal 4 (advisory vote on executive compensation) results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366198,"accession_number":"0001628280-22-016711","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All proposals pass at Cardiff annual meeting; say-on-pay vote splits nearly evenly","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; votes for ranged 14.2M–17.0M, with ~12M broker non-votes.","BDO USA ratified as auditor: 28.7M for, 487.9K against, 172.4K abstain.","Amendment to 2021 Omnibus Equity Incentive Plan approved: 14.0M for, 3.1M against, 172.1K abstain.","Advisory vote on executive compensation approved narrowly: 7.93M for, 7.36M against, 2.02M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366197,"accession_number":"0001628280-22-012620","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.","R&D expense $7.2M (up $3.9M YoY); SG&A $3.9M (up $1.7M YoY) on higher CMC, headcount, stock comp.","Phase 1b/2 mCRC: 34% initial ORR, 29% confirmed at RP2D (15 mg/m²) vs historical 5-13%; mPFS 9.4 months across all doses.","Phase 2 mCRPC: 75% disease control at 12 weeks in highest dose-density arm; mutations in PTEN/MTOR linked to response.","Preclinical: onvansertib+olaparib showed significant survival benefit vs each alone in PARPi-resistant ovarian PDX models."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":74000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366196,"accession_number":"0001628280-22-008987","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cardiff Oncology CMO Katherine Ruffner departs; Sandra Silberman named interim senior medical advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Katherine Ruffner leaving April 22, 2022; will provide transitional support.","Separation agreement includes $75,000 cash payment, base salary, unused PTO, expense reimbursement.","Sandra Silberman, former chief medical advisor (2017-2021), returns as senior medical advisor on interim basis.","Silberman has experience at Pfizer, Novartis, Eisai; currently CMO at Moleculin Biotech and CNS Pharmaceuticals.","CEO states clinical trials remain on track and on schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366195,"accession_number":"0001628280-22-008804","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cardiff Oncology announces updated Phase 2 mCRPC data and preclinical ovarian cancer data for onvansertib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.","Median progression-free survival increased from 4.1 months in Arm A to 13.2 months to-date in Arm C.","Combination of onvansertib with olaparib overcame PARP inhibitor resistance in BRCA1-mutant and wildtype PDX ovarian cancer models.","Mutations in PTEN and MTOR were positively associated with treatment response in mCRPC trial patients.","Disease control by PSA stabilization improved from 29% in Arm A to 45% in Arm C."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385684,"accession_number":"0001628280-22-003816","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.","Cash, equivalents, and short-term investments $141M as of Dec 31, 2021; Q4 operating expenses $9.6M (up from $6.6M in 2020).","Pfizer invested $15M via equity purchase of 2.4M shares at $6.22 (19% premium); Pfizer executive to join Scientific Advisory Board.","Appointed Tod Smeal as CSO (ex-Eli Lilly, Pfizer) and Charles Monahan as SVP Regulatory Affairs.","Full year 2021 net cash used in operating activities $23.0M vs $16.3M in 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":359000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385683,"accession_number":"0001628280-22-001522","cik":1213037,"company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cardiff Oncology grants 55,008 stock options to new employee as inducement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-qualified stock options for 55,008 shares granted on Jan 31, 2022 to one new employee.","Exercise price of $3.38 per share, equal to Jan 31 closing price.","Options vest over 4 years: 25% at 1-year anniversary, remainder monthly over 36 months.","Grant made under Nasdaq Listing Rule 5635(c)(4) as inducement material to employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":122177000.43977903,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-31T23:59:59+00:00|385683"}